Targeting Pro-Oxidant Iron with Deferoxamine as a Treatment for Ischemic Stroke: Safety and Optimal Dose Selection in a Randomized Clinical Trial

• Egile Nagusiak: Mònica Millán (Egilea), Núria DeGregorio-Rocasolano (Egilea), Natàlia Pérez de la Ossa (Egilea), Sílvia Reverté (Egilea), Joan Costa (Egilea), Pilar Giner (Egilea), Yolanda Silva (Egilea), Tomás Sobrino (Egilea), Manuel Rodríguez-Yáñez (Egilea), Florentino Nombela (Egilea), Francisco Campos (Egilea), Joaquín Serena (Egilea), José Vivancos (Egilea), Octavi Martí-Sistac (Egilea), Jordi Cortés (Egilea), Antoni Dávalos (Egilea), Teresa Gasull (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2021-08-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

A role of iron as a target to prevent stroke-induced neurodegeneration has been recently revisited due to new evidence showing that ferroptosis inhibitors are protective in experimental ischemic stroke and might be therapeutic in other neurodegenerative brain pathologies. Ferroptosis is a new form o...